证券之星消息，11月26日山东国企改革板块较上一交易日上涨0.45%，新华制药领涨。当日上证指数报 收于3864.18，下跌0.15%。深证成指报收于12907.83，上涨1.02%。山东国企改革板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000756 | 新华制药 | 18.15 | 5.77% | 87.79万 | 15.95 Z | | 000977 | 浪潮信息 | 63.56 | 5.74% | 99.54万 | 62.66亿 | | 002083 | 季日股份 | 9.76 | 3.50% | 161.37万 | 15.64亿 | | 000680 | 山推股份 | 10.56 | 3.02% | 38.19万 | 4.07亿 | | 301262 | 海着股份 | 28.78 | 3.01% | 22.80万 | 6.56亿 | | 001219 | 青岛食品 | 14.81 | 2.49% | 6.53万 | 9679.03万 | | 600858 | ...

Core Viewpoint - The chemical pharmaceutical sector experienced a rise of 1.66% on November 26, with Frontier Biotech leading the gains, while the overall Shanghai Composite Index fell by 0.15% [1]. Group 1: Stock Performance - Frontier Biotech (688221) closed at 20.20, up 12.85% with a trading volume of 455,500 shares and a transaction value of 916 million yuan [1]. - Yuyuan Pharmaceutical (688658) closed at 26.88, up 12.00% with a trading volume of 218,600 shares and a transaction value of 577 million yuan [1]. - Fuyuan Pharmaceutical (6801089) closed at 24.53, up 10.00% with a trading volume of 113,800 shares and a transaction value of 274 million yuan [1]. - Other notable performers include Guangji Pharmaceutical (000952) with a 9.99% increase and Beida Pharmaceutical (000788) with a 9.94% increase [1]. Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 43.08 million yuan from institutional investors, while retail investors contributed a net inflow of 23.8 million yuan [2]. - The sector experienced a net outflow of 281 million yuan from speculative funds [2]. - Key stocks with significant fund flows include Heng Rui Pharmaceutical (600276) with a net inflow of 231 million yuan from institutional investors [3]. Group 3: Individual Stock Fund Flow - New China Pharmaceutical (000756) had a net inflow of 68.2 million yuan from institutional investors, while experiencing a net outflow of 21.7 million yuan from speculative funds [3]. - Fuyuan Pharmaceutical (601089) saw a net inflow of 67.6 million yuan from institutional investors, with a net outflow of 39.4 million yuan from speculative funds [3]. - Other stocks like Beibete (688759) and Yuyuan Pharmaceutical (688658) also showed varying levels of net inflows and outflows from different investor categories [3].

Group 1 - Runjian Co., Ltd. is planning to issue H-shares and list on the Hong Kong Stock Exchange [1] - Zhongfu Shenying's shareholder plans to reduce its stake by no more than 1% [2] - Chenxi Aviation's controlling shareholder intends to reduce its stake by up to 3% [2] Group 2 - Zhiguang Electric's subsidiary signed a sales contract worth 152 million yuan [3] - Sanrenxing's controlling shareholder and actual controller plan to transfer up to 8% of the company's shares [4] - Guosheng Technology intends to acquire 100% equity of Fuyue Technology for 241 million yuan [5] Group 3 - Luxiao Technology's controlling shareholder plans to reduce its stake by no more than 3% [7] - Fusenmei's vice president and board secretary are under investigation [8] - Zhongchuang Co., Ltd. plans to transfer 2% of its shares through inquiry [10] Group 4 - Anglikang plans to raise 1.16 billion yuan for innovative drug research and industrialization projects [12] - Shenling Environment intends to issue convertible bonds to raise no more than 1 billion yuan [14] - Songcheng Performing Arts plans to acquire 100% equity of Hangzhou Songcheng Industrial for 963 million yuan [16] Group 5 - Demingli plans to raise no more than 3.2 billion yuan for SSD and DRAM expansion projects [17] - Ziyan Food's three shareholders plan to reduce their stake by no more than 276,700 shares [18] - Xinhua Pharmaceutical received a drug registration certificate for a new product [20] Group 6 - Chunqiu Electronics plans to acquire all shares of Danish liquid cooling technology company Asetek A/S for up to 547 million Danish kroner [22] - Tiandi Digital intends to transfer 100% equity of its subsidiary for 49 million yuan [24] - Huaru Technology plans to invest 20 million yuan to establish a fund focusing on new digital technologies [25] Group 7 - *ST Dongtong's stock may be suspended due to regulatory penalties for false reporting [26] - Siryipu is planning to acquire shares of Ningbo Aola Semiconductor and will suspend trading [27] - Purang Co., Ltd. is planning to acquire 49% equity of Noah Changtian and will suspend trading [29] Group 8 - *ST Suwu is facing potential delisting due to significant violations in financial reporting [32]

Core Insights - The demand for flu-related medications, testing, and online consultations has surged dramatically as many regions in China enter the flu season, leading to significant growth in pharmaceutical stocks in the A-share market, particularly in sectors such as pharmaceutical commerce, chemical pharmaceuticals, and innovative drugs [1][5]. Pharmaceutical Sector Performance - The pharmaceutical commercial sector saw an increase of 3.18%, with 28 stocks hitting the daily limit [2]. - Chemical pharmaceuticals rose by 1.97%, with 144 stocks participating in the rally [2]. - Notable stocks in the anti-flu category include Yue Wannianqing and Huaren Health, both reaching the daily limit, while Jindike surged over 14% [2][3]. Sales Data and Trends - Oseltamivir sales in Beijing skyrocketed by 237% over the past week, while another flu medication, Mabalaoshuwei, saw an increase of 180% [4][6]. - Data from Meituan indicates that since November, the demand for flu-specific medications in Beijing has increased by over 130%, with significant growth in sales for both Mabalaoshuwei and Oseltamivir [7][9]. Market Dynamics - The surge in demand for oseltamivir is attributed to its essential role in shortening illness duration and reducing severe cases, making it a necessity for households and medical institutions [9][10]. - Dongyangguang Pharmaceutical, a major supplier of oseltamivir, has established a robust supply chain to ensure stable drug availability during peak flu seasons [11]. Innovation in Flu Medications - The year 2025 is anticipated to be a landmark year for domestic flu medications, with several innovative anti-flu drugs expected to receive approval [12]. - Companies like Siheng Pharmaceutical and Health Yuan are actively submitting NDA applications for new flu treatments, indicating a growing interest in this market segment [13]. Policy and Market Support - The influx of pharmaceutical companies into the anti-flu drug market is driven by the seasonal nature of flu outbreaks and the strategic importance of the biopharmaceutical industry [14]. - National policies are increasingly focused on enhancing public health emergency capabilities, which includes optimizing emergency material reserves and improving procurement mechanisms for flu vaccines and medications [14]. - The ongoing optimization of medical insurance policies is expected to further stimulate demand for innovative anti-flu drugs, providing a solid foundation for flu-related stocks [14].

Core Viewpoint - The innovative drug sector is experiencing significant activity, with multiple companies reaching their daily price limits. Group 1: Company Performance - Zhongheng Group, Fuyuan Pharmaceutical, Hainan Haiyao, and Peking University Pharmaceutical have all hit the daily limit up [1] - Xinhua Pharmaceutical, ST Xiangxue, and Xinnowei are among the stocks with notable gains [1]

Policy Developments - The National Health Commission will hold a press conference on November 27, 2025, to discuss the progress and effectiveness of grassroots medical and health services [1] Industry Initiatives - Beijing's Economic and Information Technology Bureau, along with six departments, has introduced measures to accelerate the promotion of artificial intelligence-assisted diagnostic technologies, including financial support of up to 50 million yuan for selected projects [2] Regulatory Approvals - Saikexide has obtained registration for three medical device products, enhancing its product range in the in vitro diagnostic field [3] - Xinhua Pharmaceutical has received a drug registration certificate for a compound local anesthetic cream, with an estimated sales revenue of 615 million yuan in 2024 [4] - Heng Rui Medicine has received approval for clinical trials of its innovative anti-tumor drug HRS-8364, with a cumulative R&D investment of approximately 21.65 million yuan [5] Capital Market Activities - Suzhou High-tech plans to sell a 47% stake in its medical device subsidiary for 604 million yuan [6] - Shanghai DeYin Technology has completed a Pre-A round financing of several million yuan, backed by listed company Songlin Technology [8] Industry News - Novartis China has responded to rumors of dissolving its county-level team, stating it will adjust its operational model while continuing to serve the county medical market [9] - Samsung Medical's subsidiary has been recommended as a candidate for a procurement project with a total expected amount of approximately 107 million yuan [10] Legal Matters - Foreign companies have filed a Section 337 investigation request against specific antibody-drug conjugates, alleging infringement of trade secrets, involving companies from the US, Netherlands, and China [11] Shareholder Actions - Bid Pharma's shareholder plans to reduce their stake by up to 0.16% between December 17, 2025, and March 16, 2026, due to funding needs [12]

此外，据央广网消息，当前正值流感等呼吸道传染病高发季节，奥司他韦、玛巴洛沙韦等流感药物的需 求量不断增加。数据显示，奥司他韦近七天销量增长率达237%，玛巴洛沙韦上涨达180%。公开资料显 示，新华制药是全球重要的解热镇痛药物供应商，拥有布洛芬、阿司匹林、五安系列、美洛昔康等系列 产品。 消息面上，新华制药公告称，公司收到国家药品监督管理局核准签发的利丙双卡因乳膏《药品注册证 书》。该药品为利多卡因和丙胺卡因的复方制剂，用于皮肤局部麻醉。2024年中国公立医疗机构利丙双 卡因乳膏销售额约为6.15亿元。 山东新华制药（000756）股份(00719)再涨超4%，截至发稿，涨3.17%，报7.49港元，成交额9518.43万 港元。 ...

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has seen its stock price increase by over 4%, currently trading at 7.49 HKD, following the approval of its drug registration certificate for a new compound anesthetic cream by the National Medical Products Administration of China [1] Company Summary - The newly approved drug, Lidocaine and Prilocaine Cream, is intended for local skin anesthesia and is projected to generate sales of approximately 615 million CNY in public medical institutions in China by 2024 [1] - Xinhua Pharmaceutical is a significant global supplier of antipyretic and analgesic medications, with a product portfolio that includes Ibuprofen, Aspirin, and Meloxicam [1] Industry Summary - The current season is marked by a surge in respiratory infectious diseases, leading to increased demand for antiviral medications such as Oseltamivir and Marbofloxacin, with sales growth rates of 237% and 180% respectively over the past week [1]

每经AI快讯，11月26日，流感概念反复活跃，广济药业3连板，北大医药触及涨停，金迪克涨超10%， 海南海药涨超7%，特一药业、新华制药、金石亚药跟涨。 （文章来源：每日经济新闻） ...

证券日报网讯11月25日晚间，新华制药（000756）发布公告称，近日，山东新华制药股份有限公司(以 下简称"新华制药"或"本公司")收到国家药品监督管理局核准签发的利丙双卡因乳膏《药品注册证 书》。 ...